WFA
ESPR

Wipfli Financial Advisors’s Esperion Therapeutics ESPR Stock Holding History

Wipfli Financial Advisors’s Portfolio ESPR Stock Details ESPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		$1K Buy
+184
New +$1.26K ﹤0.01% 2407

Other funds holding ESPR

WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
MG
Meditor Group Hamilton, Bermuda $48.1M AUM 38.67% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return

Wipfli Financial Advisors's ESPR Position: Q3 2022 in Review

Wipfli Financial Advisors opened a new position in Esperion Therapeutics (ESPR) in Q3 2022: 184 shares worth $1K. The stake represents ﹤0.01% of the portfolio and ranks #2407 among its holdings.

148 funds tracked by Wall St. Rank hold ESPR as of Q3 2022.

  • Wipfli Financial Advisors held 184 shares of Esperion Therapeutics worth $1K as of Q3 2022.
  • Esperion Therapeutics was a new Wipfli Financial Advisors position in Q3 2022.
  • Esperion Therapeutics made up ﹤0.01% of Wipfli Financial Advisors's portfolio in Q3 2022, its #2407 holding.
  • 148 funds tracked by Wall St. Rank held Esperion Therapeutics as of Q3 2022.

Based on Wipfli Financial Advisors's 13F filing for Q3 2022, filed 26 Oct 2022.